In a bid to redefine value from the patient perspective, new guidelines for assessing what matters most to patients and incorporating these insights into value-based healthcare decisions have been unveiled.
The Avalere-FasterCures Patient-Perspective Value Framework (PPVF), which was launched in May 2017, is intended to provide a framework to improve treatment decisions by assessing therapies, diagnostics and other healthcare services in line with an individual’s own perceptions of value. In other words, helping patients evaluate treatments based on criteria that are meaningful to them.
By taking into account those factors that most impact people in their daily lives – including symptom relief, regimen complexity and out-of-pocket treatment costs – the aim is to better inform decision making between the patient and clinician around their care and treatment pathway. It also enables healthcare organizations to integrate the patient perspective into their own processes and public health programs as they transition to a value-based payment system.
The initiative is the brainchild of a multi-stakeholder group comprising representatives from life sciences companies, patient groups, payers and others, as well as Astellas’ own Senior Director, Health Economics and Outcomes Research – Oncology, Scott Flanders. Established in June 2016 using seed funding from FasterCures, the framework is made up of five key criteria that matter to patients when making treatment decisions, these being: patient preferences, patient-centered outcomes, patient and family costs, usability and transparency, and quality and application of evidence.
“The Patient-Perspective Value Framework really closes a hole in the value frameworks that have previously been developed and published,” said Flanders. “Many of those have not included the patient perspective, the patient preferences for value, so the Avalere and FasterCures groups approached Astellas about being at the table to better understand what components of the patient perspective need to be incorporated into these value frameworks.”
Key to the framework’s success is collaboration from all touchpoints across the healthcare continuum, with insight and participation from 23 committee members, including the Institute for Clinical and Economic Review (ICER), the American Society of Clinical Oncology (ASCO), the National Comprehensive Cancer Network (NCCN), and Memorial Sloan Kettering’s DrugAbacus.
For years, traditional definitions of value have left out the patient. Now this collaborative effort among multiple stakeholders – which will be entering its second phase in June this year – looks set to pave the way to redefine value in all facets of healthcare from drug development to clinical decision making.